CP
IRD

Caligan Partners’s Opus Genetics IRD Stock Holding History

Caligan Partners’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25M Buy
6,077,084
+2,056
+0% +$9.59K 1.18% 19
2026
Q1 		$27.6M Buy
+6,075,028
New +$21M 1.84% 16

Other funds holding IRD

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Caligan Partners's IRD Position: Q2 2026 in Review

Caligan Partners increased its Opus Genetics (IRD) stake by 0.03% in Q2 2026, buying an estimated $9.59K and bringing the position to 6,077,084 shares worth $25M. The position accounts for 1.18% of the portfolio, ranked #19.

Caligan Partners first reported a position in IRD in Q1 2026 and has held it in 2 quarters since. The position peaked at $27.6M in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Caligan Partners held 6,077,084 shares of Opus Genetics worth $25M as of Q2 2026.
  • Caligan Partners bought 2,056 Opus Genetics shares in Q2 2026, an estimated $9.59K.
  • Opus Genetics made up 1.18% of Caligan Partners's portfolio in Q2 2026, its #19 holding.
  • Caligan Partners first reported a position in Opus Genetics in Q1 2026 and has held it in 2 quarters since.
  • Caligan Partners's Opus Genetics position peaked at $27.6M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.